Premium
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study
Author(s) -
Gross Zachary,
Rahbari Ashkon,
Wirtschafter Eric,
Spektor Tanya M.,
Udd Kyle A.,
Bujarski Sean,
Ghermezi Michael,
Nosrati Jason D.,
Vidisheva Aleksandra,
Eades Benjamin,
Cecchi Gary,
Maluso Tina,
Swift Regina,
Berenson James R.
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13058
Subject(s) - lenalidomide , medicine , dexamethasone , multiple myeloma , refractory (planetary science) , regimen , oncology , retrospective cohort study , surgery , gastroenterology , physics , astrobiology
Objective To evaluate the efficacy and safety of elotuzumab and dexamethasone (Ed) for relapsed or refractory multiple myeloma ( RRMM ) patients. Method This retrospective study evaluated the efficacy and safety of Ed treatment for 21 RRMM patients, 11 of whom were considered lenalidomide‐refractory, and all of whom had progressed on at least 1 prior steroid‐containing regimen. We also evaluated the efficacy of adding lenalidomide to a subset of patients following progression from Ed. Results The overall response rate ( ORR ) and clinical benefit rate ( CBR ) of Ed were 10% and 19%, respectively. An additional 52% of patients demonstrated stable disease as their best response. The median PFS was 1.8 months on Ed for all patients. Fifteen patients received ER d following progression on Ed, and 60% of these patients were lenalidomide‐refractory. The ORR and CBR were 20% and 33%, respectively, and the median PFS was 3.4 months. Conclusion Our results suggest that some patients can benefit from Ed without an accompanying immunomodulatory agent and that efficacy can be achieved with the addition of lenalidomide at the time of progression. No new safety signals were detected, except for thrombocytopenia in 1 patient on Ed.